Callan Family Office LLC Has $3.48 Million Holdings in Stryker Corporation $SYK

Callan Family Office LLC lifted its position in shares of Stryker Corporation (NYSE:SYK - Free Report) by 112.5% during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 8,792 shares of the medical technology company's stock after purchasing an additional 4,655 shares during the quarter. Callan Family Office LLC's holdings in Stryker were worth $3,478,000 at the end of the most recent reporting period.

A number of other institutional investors also recently modified their holdings of the company. Consolidated Portfolio Review Corp raised its position in shares of Stryker by 4.2% during the second quarter. Consolidated Portfolio Review Corp now owns 648 shares of the medical technology company's stock worth $256,000 after purchasing an additional 26 shares during the period. Sunflower Bank N.A. raised its position in shares of Stryker by 4.0% during the second quarter. Sunflower Bank N.A. now owns 696 shares of the medical technology company's stock worth $275,000 after purchasing an additional 27 shares during the period. Pitti Group Wealth Management LLC raised its position in shares of Stryker by 3.2% during the second quarter. Pitti Group Wealth Management LLC now owns 861 shares of the medical technology company's stock worth $341,000 after purchasing an additional 27 shares during the period. Sachetta LLC raised its position in shares of Stryker by 58.7% during the second quarter. Sachetta LLC now owns 73 shares of the medical technology company's stock worth $29,000 after purchasing an additional 27 shares during the period. Finally, Comprehensive Financial Consultants Institutional Inc. grew its holdings in Stryker by 0.6% during the second quarter. Comprehensive Financial Consultants Institutional Inc. now owns 4,546 shares of the medical technology company's stock worth $1,799,000 after buying an additional 28 shares in the last quarter. 77.09% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on the company. Rothschild Redb upgraded Stryker to a "hold" rating in a report on Thursday, September 18th. Weiss Ratings reiterated a "buy (b-)" rating on shares of Stryker in a report on Wednesday. Rothschild & Co Redburn assumed coverage on Stryker in a report on Thursday, September 18th. They set a "neutral" rating and a $420.00 price target for the company. Redburn Partners set a $420.00 price target on Stryker in a report on Thursday, September 18th. Finally, Evercore ISI decreased their price target on Stryker from $418.00 to $410.00 and set an "outperform" rating for the company in a report on Tuesday. Fifteen research analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company's stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $430.10.

Stryker Stock Down 1.5%

SYK stock opened at $364.77 on Friday. The company has a debt-to-equity ratio of 0.70, a quick ratio of 1.06 and a current ratio of 1.78. The company has a market capitalization of $139.46 billion, a price-to-earnings ratio of 48.31, a PEG ratio of 2.67 and a beta of 0.94. Stryker Corporation has a fifty-two week low of $329.16 and a fifty-two week high of $406.19. The stock has a fifty day moving average of $380.25 and a 200-day moving average of $378.75.

Stryker (NYSE:SYK - Get Free Report) last posted its quarterly earnings results on Thursday, July 31st. The medical technology company reported $3.13 earnings per share for the quarter, topping the consensus estimate of $3.07 by $0.06. The company had revenue of $6.02 billion during the quarter, compared to the consensus estimate of $5.92 billion. Stryker had a return on equity of 23.94% and a net margin of 12.25%.The firm's quarterly revenue was up 11.1% compared to the same quarter last year. During the same quarter in the prior year, the company earned $2.81 EPS. Stryker has set its FY 2025 guidance at 13.400-13.600 EPS. As a group, equities research analysts predict that Stryker Corporation will post 13.47 earnings per share for the current year.

Stryker Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, October 31st. Stockholders of record on Tuesday, September 30th will be paid a dividend of $0.84 per share. The ex-dividend date is Tuesday, September 30th. This represents a $3.36 annualized dividend and a dividend yield of 0.9%. Stryker's dividend payout ratio is presently 44.50%.

Insider Buying and Selling at Stryker

In other news, Director Ronda E. Stryker sold 200,000 shares of the stock in a transaction on Wednesday, August 6th. The stock was sold at an average price of $376.45, for a total transaction of $75,290,000.00. Following the completion of the transaction, the director owned 3,222,108 shares in the company, valued at approximately $1,212,962,556.60. This represents a 5.84% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Viju Menon sold 500 shares of the stock in a transaction dated Monday, August 25th. The stock was sold at an average price of $390.61, for a total value of $195,305.00. Following the sale, the insider directly owned 12,511 shares in the company, valued at $4,886,921.71. This trade represents a 3.84% decrease in their position. The disclosure for this sale can be found here. 5.90% of the stock is currently owned by corporate insiders.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.